^
Association details:
| Biomarker: | ER positive + PGR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug Class: | Aromatase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer
Published date:
03/15/2022
Excerpt:
The median progression-free survival time ((PFS)) of PR+and PR- patients were 12.5 months and 9.0 months, respectively, and the difference was statistically significant (P=0.004). The clinical benefit rate (CBR) was 81.1% and 63.1%, respectively, and the difference was not statistically significant (P<0.001). PR is an independent prognostic factor of first-line AI endocrine therapy in ER-positive HER-2-negative patients.
DOI:
10.3760/cma.j.cn112137-20210708-01531
